Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Won't be 'same ole, same ole' for ODAC at Perjeta meeting

23:20 EDT 8 Aug 2013 | SCRIP

The FDA said the guidance document was intended to encourage industry innovation and expedite the development of new therapies to treat high-risk early-stage breast cancer, a disease for which there remains a significant unmet medical need in certain...

Original Article: Won't be 'same ole, same ole' for ODAC at Perjeta meeting

NEXT ARTICLE

More From BioPortfolio on "Won't be 'same ole, same ole' for ODAC at Perjeta meeting"

Search BioPortfolio: